HLA
CAI

Hamilton Lane Advisors’s Caris Life Sciences CAI Stock Holding History

Hamilton Lane Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,725
Closed -$1.58M – 28
2025
Q4 		$1.58M Buy
+58,725
New +$1.65M 0.87% 13

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Hamilton Lane Advisors's CAI Position: Q1 2026 in Review

Hamilton Lane Advisors sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 58,725 shares — an estimated $1.58M sold.

Hamilton Lane Advisors first reported a position in CAI in Q4 2025 and held it in 1 quarter. The position peaked at $1.58M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Hamilton Lane Advisors reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Hamilton Lane Advisors sold 58,725 Caris Life Sciences shares in Q1 2026, an estimated $1.58M.
  • Hamilton Lane Advisors first reported a position in Caris Life Sciences in Q4 2025 and held it in 1 quarter.
  • Hamilton Lane Advisors's Caris Life Sciences position peaked at $1.58M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Hamilton Lane Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.